ARTICLE | Clinical News

Trebananib: Additional Phase III data

November 10, 2014 8:00 AM UTC

Additional data from the double-blind, international Phase III TRINOVA-1 trial in over 900 women with recurrent partially platinum-sensitive or platinum-resistant ovarian cancer, primary peritoneal cancer or fallopian tube cancer showed that once-weekly 15 mg/kg IV trebananib plus paclitaxel missed the secondary endpoint of improving OS vs. placebo plus paclitaxel (19.3 vs. 18.3 months). Amgen previously reported that trebananib plus paclitaxel met the primary endpoint of improving median PFS vs. placebo plus paclitaxel (7.2 vs. 5.4 months, p<0.001). At that time, the company said a pre-planned interim analysis of the secondary OS endpoint showed a trend in favor of trebananib (see BioCentury, June 17, 2013). ...